Dexcel Pharma Executive and Leadership Team

Ufuoma Ezekiel, the Chief Executive Officer at Dexcel Pharma, directs the overarching corporate strategy and operational execution. Overseeing the company's expansion into key international markets such as the U.S. and Germany, Ezekiel ensures alignment with Dexcel Pharma's mission to deliver high-quality pharmaceutical products. This leadership role involves guiding the development and commercialization of branded prescription drugs, generics, and OTC products, with a particular focus on oral solid dosage forms. Ezekiel drives initiatives to enhance manufacturing efficiency and product portfolio diversification. By fostering cross-functional collaboration, Ufuoma Ezekiel ensures that Dexcel Pharma maintains its competitive edge and continues its growth trajectory as Israel's largest privately owned pharmaceutical entity. The Chief Executive Officer's strategic vision shapes the company's response to evolving market demands and regulatory landscapes across its global supply chain.

Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, collaborates with the Chief Executive Officer to steer the company's strategic direction and operational oversight. Oren focuses on optimizing the development, manufacturing, and commercialization processes for Dexcel Pharma's extensive range of value-added branded prescription drugs, generics, and OTC products. This involves ensuring robust supply chain management and adherence to stringent quality standards across all oral solid dosage forms. Oren drives initiatives aimed at expanding market reach in territories including the U.K. and Austria, leveraging Dexcel Pharma's established network of subsidiaries and distribution partners. The Co-Chief Executive Officer's leadership ensures seamless integration of new product pipelines and enhances the company's capacity to meet diverse patient needs globally. By championing operational excellence, Ilan Oren contributes significantly to Dexcel Pharma's sustained market leadership and commitment to pharmaceutical innovation.

Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, directs all financial planning, management, and reporting activities. Erez oversees the fiscal health of the organization, ensuring robust financial controls and strategic resource allocation to support Dexcel Pharma's global operations and product development initiatives. This includes managing budgets for the manufacturing of branded prescription drugs, generics, and OTC products, as well as overseeing financial strategies for market expansion in key regions like the U.K. and Austria. Erez plays a critical role in evaluating investment opportunities, optimizing capital structure, and ensuring compliance with international financial regulations. By providing strategic financial insights, Yaron Erez enables informed decision-making across all departments, driving profitability and sustainable growth for Dexcel Pharma. The Chief Financial Officer & Vice President's expertise is fundamental to the company's long-term financial stability and strategic objectives.

Miri Peleg, the Chief Information Officer & Vice President at Dexcel Pharma, architects and executes the company's comprehensive information technology strategy. Peleg oversees the integration of advanced digital solutions across all facets of Dexcel Pharma's operations, from research and development to manufacturing and commercialization. This leadership role ensures the security, scalability, and efficiency of IT infrastructure supporting the production of branded prescription drugs, generics, and OTC products. Peleg drives digital transformation initiatives that enhance data analytics capabilities, streamline supply chain visibility, and improve customer relationship management in markets like the U.S. and Germany. By championing technological innovation, Miri Peleg empowers Dexcel Pharma to optimize its product development cycles and expand its market presence. The Chief Information Officer & Vice President's strategic guidance is crucial for maintaining operational agility and fostering a data-driven culture throughout the organization.

Esther Hagai, the Chief Medical Officer at Dexcel Pharma, leads the company's medical affairs strategy and clinical development programs. Hagai oversees the scientific and clinical evaluation of Dexcel Pharma's product portfolio, including branded prescription drugs, generics, and OTC products, ensuring adherence to the highest medical and ethical standards. This leadership role involves guiding clinical research, post-market surveillance, and the generation of robust scientific data to support product efficacy and safety in markets worldwide. Hagai collaborates closely with R&D and commercial teams to align medical strategies with business objectives, particularly for oral solid dosage forms. The Chief Medical Officer's expertise is vital in navigating complex regulatory environments and communicating scientific value to healthcare professionals and regulatory bodies. By championing evidence-based medicine, Esther Hagai reinforces Dexcel Pharma's commitment to improving patient health outcomes and advancing pharmaceutical science.